{"abstract": "Briggs Morrison, who oversees drug development for AstraZeneca, says the company would be better off without Pfizer. He bases that, in part, on having worked at Pfizer.", "web_url": "https://dealbook.nytimes.com/2014/05/07/a-scientists-defense-of-keeping-astrazeneca-independent/", "snippet": "Briggs Morrison, who oversees drug development for AstraZeneca, says the company would be better off without Pfizer. He bases that, in part, on having worked at Pfizer.", "lead_paragraph": "Updated, 1:13 p.m. | LONDON \u2014 It is probably no surprise that Briggs Morrison, head of global drug development at AstraZeneca, has sided with his bosses in opposing the idea of the American giant Pfizer taking over the British company.", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "xlarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/08/business/dbpix-drug2/dbpix-drug2-articleLarge.jpg", "height": 400, "width": 600, "subType": "xlarge", "crop_name": "articleLarge", "legacy": {"xlarge": "images/2014/05/08/business/dbpix-drug2/dbpix-drug2-articleLarge.jpg", "xlargewidth": 600, "xlargeheight": 400}}, {"rank": 0, "subtype": "jumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/08/business/dbpix-drug2/dbpix-drug2-jumbo.jpg", "height": 683, "width": 1024, "subType": "jumbo", "crop_name": "jumbo", "legacy": {}}, {"rank": 0, "subtype": "superJumbo", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/08/business/dbpix-drug2/dbpix-drug2-superJumbo.jpg", "height": 1365, "width": 2048, "subType": "superJumbo", "crop_name": "superJumbo", "legacy": {}}, {"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/08/business/dbpix-drug2/dbpix-drug2-thumbStandard.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2014/05/08/business/dbpix-drug2/dbpix-drug2-thumbStandard.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}, {"rank": 0, "subtype": "thumbLarge", "caption": null, "credit": null, "type": "image", "url": "images/2014/05/08/business/dbpix-drug2/dbpix-drug2-thumbLarge.jpg", "height": 150, "width": 150, "subType": "thumbLarge", "crop_name": "thumbLarge", "legacy": {}}], "headline": {"main": "A Scientist\u2019s Defense of Keeping AstraZeneca Independent", "kicker": "DealBook", "content_kicker": null, "print_headline": "", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 2, "major": "N"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": 3, "major": "N"}, {"name": "organizations", "value": "AstraZeneca PLC", "rank": 4, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 5, "major": "N"}], "pub_date": "2014-05-07T15:42:01+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Jenny Anderson", "person": [{"firstname": "Jenny", "middlename": null, "lastname": "Anderson", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/e6962748-39b1-5842-a4ed-a6e1df58ec31", "word_count": 734, "uri": "nyt://article/e6962748-39b1-5842-a4ed-a6e1df58ec31"}